2. NF-κB Immunology/Inflammation Apoptosis Metabolic Enzyme/Protease
  3. NF-κB NO Synthase Interleukin Related TNF Receptor Cytochrome P450
  4. N,N-Diethylacetamide

N,N-Diethylacetamide is a polar solvent widely used in film and fiber manufacturing, as well as in laboratories as a carrier for water-insoluble chemicals. N,N-Diethylacetamide exerts potent anti-inflammatory effects by inhibiting the NF-κB pathway, suppressing the expression of NO and iNOS, and downregulating key inflammatory cytokines such as TNF-α and IL-6, without affecting the MAPK pathway. N,N-Diethylacetamide can be used to study inflammatory preterm birth.

For research use only. We do not sell to patients.

N,N-Diethylacetamide

N,N-Diethylacetamide Chemical Structure

CAS No. : 685-91-6

Size Price Stock Quantity
100 mg In-stock
500 mg In-stock
1 g In-stock
5 g In-stock
10 g In-stock
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

N,N-Diethylacetamide Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms
CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A CYP3A4 CYP17A1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

N,N-Diethylacetamide is a polar solvent widely used in film and fiber manufacturing, as well as in laboratories as a carrier for water-insoluble chemicals. N,N-Diethylacetamide exerts potent anti-inflammatory effects by inhibiting the NF-κB pathway, suppressing the expression of NO and iNOS, and downregulating key inflammatory cytokines such as TNF-α and IL-6, without affecting the MAPK pathway. N,N-Diethylacetamide can be used to study inflammatory preterm birth.

IC50 & Target

NF-κB

 

IL-1β

 

IL-6

 

IL-8

 

CYP2B1

 

CYP2B2

 

In Vitro

N,N-Diethylacetamide (10 mM; 26 h) inhibits LPS (HY-D1056)-stimulated NO secretion in RAW 264.7 cells[1].
N,N-Diethylacetamide (10 mM; 8 h) reduces LPS-induced iNOS expression in RAW 264.7 cells[1].
N,N-Diethylacetamide (0.1-10 mM; 26 h) inhibits LPS-stimulated IL-6, IL-8, and MCP-1 secretion in HTR-8/SVneo cells[1].
N,N-Diethylacetamide (10 mM; 26 h) suppresses LPS-stimulated TNF-α, IL-6, IL-1β, GM-CSF, MCP-1, and IL-10 secretion in RAW 264.7 cells[1].
N,N-Diethylacetamide (0.1-10 mM; 22 h) inhibits LPS-stimulated cytokine and chemokine secretion in human placental explants[1].
N,N-Diethylacetamide (10 mM; 2.25 h) prevents LPS-induced IkB-α degradation in RAW 264.7 cells[1].
N,N-Diethylacetamide (10 mM; 26 h) does not alter LPS-stimulated MAPK pathway protein expression in RAW 264.7 cells[1].
N,N-Diethylacetamide (10 mM; 26 h) inhibits LPS-stimulated NF-κB transcriptional activity in HEK 293 cells overexpressing TLR4, without affecting AP-1 or C/EBP activity[1].
N,N-Diethylacetamide (0.5-10 mM; 50 min) was catalyzed for deethylation by purified P4502B1 with a Km of 3.5 mM[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

N,N-Diethylacetamide Related Antibodies

Cell Viability Assay[1]

Cell Line: HTR-8/SVneo, RAW 264.7, HEK 293
Concentration: up to 10 mM
Incubation Time: 2 h (pre-treatment); 24 h (LPS treatment)
Result: Did not significantly affect the viability of HTR-8/SVneo, RAW 264.7, or HEK 293 cells compared to untreated controls.

Western Blot Analysis[1]

Cell Line: RAW 264.7
Concentration: 0.1, 1, 10 mM
Incubation Time: 2 h (pre-treatment); 6 h (LPS treatment)
Result: Significantly inhibited LPS-induced iNOS expression in RAW 264.7 cells at 10 mM (P < 0.001) compared to LPS control.

ELISA Assay[1]

Cell Line: HTR-8/SVneo
Concentration: 0.1, 1, 10 mM
Incubation Time: 2 h (pre-treatment); 24 h (LPS treatment)
Result: Significantly suppressed LPS-stimulated IL-6 secretion at 10 mM (more effectively than BAY 11-7082), caused a 90% reduction in IL-8 secretion at 10 mM (more effective than BAY 11-7082), and significantly inhibited MCP-1 secretion at 1 and 10 mM.

ELISA Assay[1]

Cell Line: RAW 264.7
Concentration: 0.1, 1, 10 mM
Incubation Time: 2 h (pre-treatment); 24 h (LPS treatment)
Result: Significantly reduced TNF-α (P < 0.0001), IL-6, IL-1β, GM-CSF (>90% reduction), MCP-1, and IL-10 (P < 0.0001) secretion from LPS-stimulated RAW 264.7 cells at 10 mM.

Western Blot Analysis[1]

Cell Line: RAW 264.7
Concentration: 0.1, 1, 10 mM
Incubation Time: 2 h (pre-treatment); 15 min (LPS treatment)
Result: Significantly inhibited LPS-induced IkB-α degradation in RAW 264.7 cells at 10 mM (P < 0.01) compared to LPS control.\nDid not affect LPS-stimulated expression of native or phosphorylated JNK1, ERK1/2, or p38 MAPK in RAW 264.7 cells at any concentration.
In Vivo

N,N-Diethylacetamide (375-750 mg/kg; i.p.; two doses) delays LPS-induced preterm birth in a dose-dependent manner, with 750 mg/kg completely preventing delivery for at least 25 h[1].
N,N-Diethylacetamide (150-500 mg/kg; i.p.; daily; 3 days) administration to rats induces P4502B1/2 and alters hepatic drug-metabolizing enzyme activities in a dose-dependent manner, with higher doses causing hepatotoxicity[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57Bl/6 (timed pregnant, weight 27–36 g)[1]
Dosage: 375 mg/kg; 750 mg/kg
Administration: i.p.; two doses (T=-15 min and T=10 h)
Result: Prevented delivery in all 6 mice treated with 750 mg/kg by 25 h post-LPS injection.
Delayed mean delivery time by approximately two hours and prevented delivery in 2/8 mice treated with 375 mg/kg by 25 h post-LPS injection.
Animal Model: Sprague-Dawley (male, 5-6 weeks old)[2]
Dosage: 150, 300 mg/kg; 400-500 mg/kg
Administration: i.p.; daily; 3 days
Result: Significantly induced the enzymatic activities related to CYP2B1/2 (such as PROD, 16β-testosterone hydroxylation), and enhanced its own metabolism (DEAC deethylase activity).
Increased the expression of CYP2B1/2 protein, while inhibiting the expression of CYP2C11.
Molecular Weight

115.17

Formula

C6H13NO
CAS No.
Appearance

Liquid (Density: 0.925 g/cm3)

Color

Colorless to light yellow

SMILES

CCN(C(C)=O)CC
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

N,N-Diethylacetamide Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

N,N-Diethylacetamide685-91-6NF-κBNO SynthaseInterleukin RelatedTNF ReceptorCytochrome P450Nuclear factor-κBNuclear factor-kappaBNitric oxide synthasesNOSILTumor Necrosis Factor ReceptorTNFRCYPsNF-κB pathwaycytochrome P450 2C11HTR-8/SVneocytochrome P450 2B1/2ratsinducible nitric oxide synthase (iNOS)MAPK pathwayRAW 264.7HEK 293LPSInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
N,N-Diethylacetamide
Cat. No.:
HY-W008829
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (394 KB) Français - FR (394 KB) Deutsch - DE (394 KB) Norwegian - NO (394 KB) Español - ES (394 KB) Swedish - SV (394 KB) Italian - IT (394 KB) Korean - KR (394 KB) Portuguese - PT (394 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.